Editas Medicine (NASDAQ:EDIT) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report released on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the subject of a number of other research reports. Oppenheimer reissued a market perform rating and set a $12.00 price objective on shares of […]